Cereno Scientific has reported initial findings from a 12-month Expanded Access Program (EAP) with its oral drug candidate CS1 in pulmonary arterial hypertension (PAH), enrolling ten patients who had completed the previous Phase IIa trial. The results confirm a favourable safety and tolerability profile over long-term use, consistent with earlier findings, with no unexpected safety concerns and no deaths reported. Six of the ten patients completed the full 12 months of treatment.
Together with the Phase IIa trial, the Expanded Access Program provides up to 15 months of treatment experience, further supporting CS1’s potential as an oral, once-daily disease-modifying therapy for pulmonary arterial hypertension.
A larger placebo-controlled global Phase IIb study is currently in preparation, with first patient enrolment anticipated in June 2026.
Read more on the company press release at this link